Head-to-head evidence
Globalagliatin Hydrochloride vs PB-201
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
Globalagliatin Hydrochloride
Developed by Yabao Pharmaceutical Group
NCT03414892 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
PB-201
Developed by PegBio
NCT05102149 · Phase 3 · status unknown
This is a randomized, fully blinded trial with both an active and a placebo comparator, testing a recognized clinical measure (HbA1c) in a reasonably large group of patients, but no results are available yet to confirm whether PB-201 met its goal.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Globalagliatin Hydrochloride's landscape · PB-201's landscape